Biology Reference
In-Depth Information
Brueckner, R.P., et al., 1998. First-time-in-humans safety and pharmacokinetics of WR
238605, a new antimalarial. Am. J. Trop. Med. Hyg. 58 (5), 645-649.
Carlton, J.M., Sina, B.J., Adams, J.H., 2011. Why is
Plasmodium vivax
a neglected tropical
disease?. PLoS Negl. Trop. Dis. 5 (6), e1160.
Carmona-Fonseca, J., Maestre, A., 2009. Prevention of
Plasmodium vivax
malaria recurrence:
efficacy of the standard total dose of primaquine administered over 3 days. Acta Trop.
112 (2), 188-192.
Chen, J.H., et al., 2010. Detection of
Plasmodium vivax
infection in the Republic of Korea by
loop-mediated isothermal amplification (LAMP). Acta Trop. 113 (1), 61-65.
Chotivanich, K., et al., 2009. Antimalarial drug susceptibility of
Plasmodium vivax
in the
Republic of Korea. Am. J. Trop. Med. Hyg. 80 (6), 902-904.
Clyde, D.F., McCarthy,V.C., 1977. Radical cure of Chesson strain vivax malaria in man by 7,
not 14, days of treatment with primaquine. Am. J. Trop. Med. Hyg. 26 (3), 562.
Coatney, G.R., Getz, M.E., 1962. Primaquine and quinocide as curative agents against spo-
rozoite-induced Chesson strain vivax malaria. Bull. World Health Organ. 27, 290-293.
Coatney, G.R., et al., 1950. Studies in human malaria: XVIII. The life pattern of sporozoite-
induced St. Elizabeth strain vivax malaria. Am. J. Hyg. 51 (2), 200.
Coatney, G.R., et al., 1953. Korean vivax malaria. Am. J. Trop. Med. Hyg. 2 (6), 985-988.
Collins, W.E., Jeffery, G.M., 1996. Primaquine resistance in
Plasmodium vivax
. Am. J. Trop.
Med. Hyg. 55 (3), 243.
Crockett, M., Kain, K.C., 2007. Tafenoquine: a promising new antimalarial agent. Expert
Opin. Investig. Drugs 16 (5), 705-715.
Dao, N.V.H., et al., 2007. Vivax malaria: preliminary observations following a shorter course
of treatment with artesunate plus primaquine. Trans. R. Soc. Trop. Med. Hyg. 101 (6),
534-539.
Darlow, B., et al., 1982. Sulfadoxine-pyrimethamine for the treatment of acute malaria in
children of Papua New Guinea. II.
Plasmodium vivax
. Am. J. Trop. Med. Hyg. 31 (1),
10-13.
Denis, M.B., et al., 2006. Efficacy of artemether-lumefantrine for the treatment of uncom-
plicated falciparum malaria in northwest Cambodia. Trop. Med. Int. Health 11 (12),
1800-1807.
Douglas, N.M., et al., 2010. Artemisinin combination therapy for vivax malaria. Lancet
Infect. Dis. 10 (6), 405-416.
Douglas, N.M., et al., 2011.
Plasmodium vivax
recurrence following falciparum and mixed
species malaria: risk factors and effect of antimalarial kinetics. Clin. Infect. Dis. 52 (5),
612-620.
Douglas, N.M., et al., 2012. The anaemia of
Plasmodium vivax
malaria. Malar. J. 11 (1), 135.
Elmes, N.J., et al., 2008. The efficacy and tolerability of three different regimens of tafeno-
quine versus primaquine for post-exposure prophylaxis of
Plasmodium vivax
malaria in
the Southwest Pacific. Trans. R. Soc. Trop. Med. Hyg. 102 (11), 1095-1101.
Ezzet, F., et al., 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflume-
tol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44 (3), 697-704.
Feachem, R.G., et al., 2010. Shrinking the malaria map: progress and prospects. Lancet 376
(9752), 1566-1578.
Flower, B., et al., 2011. Blind, breathless, and paralysed from benign malaria. Lancet 377
(9763), 438.
Gama, B.E., et al., 2011. Chemoresistance of
Plasmodium falciparum
and
Plasmodium vivax
parasites in Brazil: consequences on disease morbidity and control. Mem. Inst. Oswaldo
Cruz 106 (Suppl. 1), 159-166.
Garfield, R.M., Vermund, S.H., 1983. Changes in malaria incidence after mass drug admin-
istration in Nicaragua. Lancet 2 (8348), 500-503.
